alexa Devices And Rationale For Intradermal Injection Of Vaccines
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Zach Marks
Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.022
Abstract
I nterest in intradermal injection is growing due to interest in dose sparing and the immunogenicity of the dermal layer along with other factors. There are currently over 60 ongoing trials evaluating intradermal injection and the first intradermal vaccine for flu has been on the market for 3 years. Adoption of intradermal injection has been slow due to the difficulty in learning and mastering The Mantoux technique. Realizing the need for simpler, cost effective and more reliable intradermal injections, we developed an injection guide for minimizing the variability and complexity of the Mantoux technique, thereby providing predictable, reproducible bleb formation. The guide assures that the ideal angle and depth of needle insertion for successful intradermal injections. Results from West?s clinical trials show the success of the novel injection guide while market research has shown a high level of nurse satisfaction with the technique and a preference for the guide over the standard needle and syringe. Developing an intradermal vaccine requires a reproducible technique, understanding of the dose response relationship of both IM and ID injection, and clinical trials to prove protection compared to the standard of care
Biography
Zach Marks joined West Pharmaceutical Services in 2002 as Business Development Manager. In 2007, with the acquisition of Medimop Medical Products, he was chosen for the position of Marketing and Business Development Manager for the group. During his tenure, his leadership and market knowledge helped expand the business into new accounts, products, therapeutic areas and geographies. In 2010, he was appointed Director, Strategic Marketing and Innovation within the Delivery Systems Business Unit where his combined experiences have been instrumental in establishing the marketing structure, function and resources that have resulted in consistent growth of revenue and profitability. He has prior experience including laboratory, sales, marketing and management roles with Johnson and Johnson and Waters Corporation. He is a registered pharmacist with a BS in Pharmacy and an MS in Pharmaceutical Science from Rutgers University.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords